CHRS vs BIIB: Which Stock is Better?
Side-by-side comparison of Coherus Oncology Inc and Biogen Inc in 2026
CHRS
Coherus Oncology Inc
$1.99
BIIB
Biogen Inc
$183.34
Key Metrics Comparison
| Metric | CHRS | BIIB | Winner |
|---|---|---|---|
| Market Cap | $296.78M | $26.91B | BIIB |
| P/E Ratio | N/A | 20.88 | BIIB |
| EPS (TTM) | $N/A | $8.78 | BIIB |
| Revenue Growth | 0.6% | -0.1% | CHRS |
| Gross Margin | 67.2% | 78.9% | BIIB |
Analyze CHRS
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHRS or BIIB a better investment?
Comparing CHRS and BIIB: Coherus Oncology Inc has a market cap of $296.78M while Biogen Inc has $26.91B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHRS and BIIB?
CHRS (Coherus Oncology Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHRS or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHRS or BIIB?
CHRS has higher revenue growth at 0.6% vs -0.1% for BIIB.
Which company is more profitable: CHRS or BIIB?
Biogen Inc (BIIB) has higher gross margins at 78.9% compared to 67.2% for CHRS.
Which is the larger company: CHRS or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $26.91B compared to $296.78M for CHRS.
Should I buy CHRS or BIIB in 2026?
Both CHRS and BIIB have investment merit. CHRS trades at $1.99 while BIIB trades at $183.34. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHRS and BIIB stock?
Key differences: Market Cap ($296.78M vs $26.91B), P/E Ratio (N/A vs 20.9x), Revenue Growth (0.6% vs -0.1%), Gross Margin (67.2% vs 78.9%).